Ligand Pharmaceuticals (LGND) Gross Profit (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Gross Profit data on file, last reported at $48.4 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 19.67% year-over-year to $48.4 million; the trailing twelve-month figure through Mar 2026 stood at $261.5 million (up 55.24% YoY), and the FY2025 full-year result was $253.5 million, up 62.46% from the prior year.
• Gross Profit fell to $48.4 million in Q1 2026, from $56.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $111.7 million in Q3 2025 to a low of $24.7 million in Q2 2023.
• A 5-year average of $42.5 million and a median of $40.0 million in 2024 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit sank 35.24% in 2022 and soared 126.2% in 2025, its largest moves.
• Tracing LGND's Gross Profit over 5 years: stood at $28.8 million in 2022, then declined by 8.02% to $26.5 million in 2023, then soared by 51.08% to $40.0 million in 2024, then soared by 41.77% to $56.7 million in 2025, then fell by 14.51% to $48.4 million in 2026.
• Business Quant data shows LGND's Gross Profit at $48.4 million in Q1 2026, $56.7 million in Q4 2025, and $111.7 million in Q3 2025.